Print Friendly and PDF

Sanders in Canada: U.S. drug prices ‘an embarrassment’

July 28, 2019

The Detroit News

Jonathan Oosting 

The FDA is hoping a new congressional mandate to regulate medication like insulin as “biologics” rather than a drug could encourage production of “biosimilar competition” and lower-cost versions.

Sanders is a leading advocate for a nationalized health care proposal known as Medicare for All that would eliminate private insurance in favor of a single-payer government system. He said the plan would cap yearly prescription drug bills at $200 and drive down costs by using Medicare to negotiate with drug companies.

The proposal appears relatively popular with Democratic primary voters, but Michigan general election voters oppose the strict Medicare for All plan by a margin of 52%-37%, according to a July 17-20 poll conducted by Glengariff Group Inc. and commissioned by the Detroit Regional Chamber.

Republican President Donald Trump has bashed Medicare for All, arguing it is a “radical socialist” idea that would cause taxes to “skyrocket” and could jeopardize the traditional health insurance program for seniors.

Sanders has introduced Senate legislation that seeks to reduce prescription drug prices by giving the federal government power to authorize generic versions of name-brand medication if pharmaceutical companies charge more than the median price in five other major industrialized countries, including Canada and the United Kingdom.

View the full article here